Fig. 2

Biomarker levels in survivors versus non-survivors. Biomarker levels were assessed at month six (BGM, C1M, EL-NE, Pro-C6) or year one (C3A, C3M, C4M, C6M, CRPM, ELM7, CRP, fibrinogen) in survivors (n = 970) and non-survivors (n = 30). All biomarkers, with the exception of BGM, EL-NE, and fibrinogen, were significantly elevated in non-survivors compared to survivors. Data are shown as geometric mean ± SEM. Statistical significance was determined using student’s t-test: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001